SCHEMBL6527378

SCHEMBL6527378

COc1cc2c(C(=O)O)c(Sc3ccccc3)n(C)c2cc1Br

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.62
MEN1 O00255 4/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 4/20 0.47
TSHR P16473 2/20 0.47
ATM Q13315 2/20 0.44
HTT P42858 2/20 0.41
POLB P06746 2/20 0.41
MITF O75030 1/20 0.41
SPR P35270 1/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPSR1 Q6W5P4 1/20 0.39
PABPC1 P11940 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14158941 0.77 KMT2A (1.00) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL2864474 0.74 ALDH1A1 (0.61) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL2857744 0.73 KMT2A (0.70) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL4764429 0.71 EDNRB (0.59) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6524004 0.70 KMT2A (0.60) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6519781 0.68 TSHR (0.77) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL28715223 0.67 ATM (0.54) KMT2AMEN1L3MBTL1ALDH1A1CYP1A2
SCHEMBL24236643 0.67 MEN1 (0.49) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25946347 0.66 ALDH1A1 (1.00) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL14621743 0.66 ALDH1A1 (0.59) KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065919-A1 5-Substituted Indol-3-Carboxylic Acid Derivatives Exhibiting Antiviral Activity a Method for the Production and Use Thereof OOO "BINATEKH" (RU) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065919-A1 5-Substituted Indol-3-Carboxylic Acid Derivatives Exhibiting Antiviral Activity a Method for the Production and Use Thereof CBR3, IFNAR1, SIGMAR1 KMT2A 4466/4885MEN1 4185/4885L3MBTL1 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.